{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.35 vs. cons $0.34",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.11B vs. cons $1.10B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EBITDA margin",
      "prediction": "IN-LINE",
      "answer": "pred ~23.3% vs. cons 23.2%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Organic revenue growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~7.5% vs. cons 7.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "M&A revenue contribution",
      "prediction": "UNCHANGED",
      "answer": "guide ~2.5% vs. cons 2.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Core adjusted incremental EBITDA margin",
      "prediction": "UNCHANGED",
      "answer": "guide ~32.5% vs. cons 32.5% (medium-term/FY2026 framework)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Free-cash-flow conversion",
      "prediction": "UNCHANGED",
      "answer": "guide ~105% vs. cons 105% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": 0.8,
  "day5_path": "FADE",
  "day5_rationale": "A modest ~$0.35 EPS versus $0.34 consensus beat and ~$1.11B revenue versus $1.10B consensus should support an initial +2.5% residual move, but unchanged FY2026 organic-growth, M&A, margin, and cash-conversion framing limits out-period estimate revisions; the residual likely fades to +0.8% by day 5.",
  "day5_confidence": "LOW"
}